Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
1.
J Environ Manage ; 314: 115010, 2022 Jul 15.
Article in English | MEDLINE | ID: mdl-35447444

ABSTRACT

Anthropogenic microparticles (e.g., microplastics) are present in sewage plants, especially in sludge streams. However, the lack of standardized protocols to scrutinize the presence of anthropogenic microparticles in sludge makes the comparison between studies unfeasible. To tackle the knowledge gap regarding the efficiency of methodologies on the extraction of anthropogenic microparticles from the complex organic matrix, dewatered sludge, and digested sludge was treated with peroxidation and density separation, and the recovery of microparticles from these samples was investigated. The results showed that with the use of a higher density solution (NaI, 1.5 g/cm3) a much better recovery of anthropogenic microparticles from sludge samples (approximately 1000 microparticles/g-dw and 2000 microparticles/g-dw, from dewatered and digested sludge, respectively) was achieved in comparison with the use of a lower density solution (NaCl, 1.2 g/cm3) (200 microparticles/g-dw and 600 microparticles/g-dw from dewatered and digested sludge, respectively). Moreover, although the use of peroxidation is an essential step to break down the sludge structure and to release microparticles to the liquid phase, the use of peroxidation after or before density separation did not affect the overall recovery of microparticles. Polyethylene, polypropylene, and copolymer ethylene-ethyl-acrylate were the main microplastic fragments identified in digested sludge and dewatered sludge. However, no relation was observed between the method applied and the polymer recovered. Regarding the presence of anthropogenic microparticle in centrifuge effluent, 450 ± 212 microparticles/L were counted, and although little is known about this stream, in can be a relevant source of anthropogenic microparticles.


Subject(s)
Microplastics , Sewage , Plastics , Polyethylene , Polymers , Polypropylenes , Sewage/chemistry
4.
Domest Anim Endocrinol ; 69: 13-18, 2019 10.
Article in English | MEDLINE | ID: mdl-31103887

ABSTRACT

The objective of this study was to determine whether the amount of protein provided to cows during late gestation would affect postnatal growth and lead to changes in glucose and insulin concentrations. At 129 d of gestation, 10 mature multiparous Angus cows were stratified by body weight (BW) and body condition score (BCS) and allotted to either low protein level (LP, 6% crude protein [CP]) or high protein level (HP, 12% CP) groups. After calving, cows were managed together on improved pastures, which provided forage in excess of requirements until weaning. Male calves were maintained as a group after weaning on native range until 23 mo of age when individual steers were placed in single pens and fed a finishing diet for 84 d. The 12th rib fat thickness and longissimus muscle area were measured during finishing phase by ultrasound. Twenty days before the end of the finishing phase, steers were subjected to an intravenous glucose tolerance test. Steers were harvested and carcass characteristics collected. Cows' BW and BCS were similar at the initiation of treatment. During treatment HP dams gained 21 kg, whereas LP dams lost 7 kg (P = 0.04). Protein nutrition during late gestation did not influence calf birth weight, BW at weaning, adjusted 205 d BW, or average daily gain during lactation (P > 0.10). Longissimus muscle area measure by ultrasound was greater (P = 0.02) in HP steers at the beginning and end of finishing phase. Fat thickness of the 12th rib was not different (P > 0.10) between treatments. Glucose concentration after intravenous administration decreased (P = 0.002) in LP compared with HP steers. Peak of serum insulin concentration was greater (P = 0.04) and serum insulin concentration tended to decrease (P = 0.08) more rapidly in LP compared with HP steers after glucose infusion. At harvest, hot carcass weight was similar between treatments, but dressing percentage was increased (P = 0.05) in HP compared with LP steers. These data demonstrate that a lower protein nutrition level of dams during late gestation affect carcass characteristics and alter glucose regulation enhancing insulin secretion in steer progeny.


Subject(s)
Cattle/physiology , Dietary Proteins/administration & dosage , Glucose/metabolism , Muscle, Skeletal/growth & development , Pregnancy, Animal , Animal Feed/analysis , Animal Nutritional Physiological Phenomena , Animals , Diet/veterinary , Female , Male , Pregnancy , Prenatal Nutritional Physiological Phenomena
6.
Ann Hematol ; 96(1): 9-16, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27752822

ABSTRACT

Autologous hematopoietic cell transplantation (AHCT) is the standard of care for young patients with relapsed/refractory (R/R) Hodgkin's lymphoma (HL). However, there is limited experience of its efficacy and feasibility in older patients. The characteristics and outcomes of 121 patients aged ≥50 years (42 of them are ≥60 years old) with R/R HL who underwent AHCT were reviewed. After a median follow-up of 3.1 years, overall survival (OS) and progression-free survival (PFS) at 5 years were 64 and 55 %, respectively, with no differences between 50-59-year-old and ≥60-year-old patients. Hematological and extra-hematological toxicities after AHCT were comparable between the two groups of age. In univariate analysis, poorer OS and PFS were associated with disease status other than complete remission, hematopoietic cell transplantation comorbidity index (HCT-CI) scores >1, and Charlson Comorbidity Index (CCI) scores >1. HCT-CI scores >1 were also associated with a higher risk of grade 3-4 extrahematologic toxicity. In multivariate analysis, HCT-CI and CCI remained significantly associated with OS and PFS after adjustment for disease status. Our data show that AHCT can be performed in selected patients with R/R HL ≥50 years with acceptable outcome and toxicity. Comorbidities appear to impact AHCT outcome more than age.


Subject(s)
Hematopoietic Stem Cell Transplantation/trends , Hodgkin Disease/diagnosis , Hodgkin Disease/therapy , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/therapy , Age Factors , Aged , Comorbidity , Disease-Free Survival , Female , Hematopoietic Stem Cell Transplantation/mortality , Hodgkin Disease/mortality , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/mortality , Predictive Value of Tests , Retrospective Studies , Transplantation, Autologous/mortality , Transplantation, Autologous/trends , Treatment Outcome
8.
Rev Neurol ; 62(12): 549-54, 2016 Jun 16.
Article in Spanish | MEDLINE | ID: mdl-27270676

ABSTRACT

INTRODUCTION: Headache as a symptom is a very common disease and one of the main reasons for consultation in primary care. AIM: To analyze the characteristics of patients referred from primary care to general neurology whose chief complaint was headache and/or neuralgia and diagnostic agreement. PATIENTS AND METHODS: Cross-sectional study of all patients referred from primary care; demographic/clinical variables were collected and diagnostic hypothesis by primary care and general neurology were compared by determining their agreement. RESULTS: 2,514 were referred from primary care patients (588 of them on a preferential basis); in 378 cases the reason for consultation was headache and/or neuralgia (average 42.46 years; 77.8% female). In 139 patients it was established only a semiological diagnostic and other episodic migraine predominated (49.79%), chronic tension headache (18.41%) and trigeminal neuralgia (12.13%). Since general neurology, the most common diagnoses were, respectively, 33.86%, 24.05% and 18.67%. A compatible kappa coefficient of 0.543 (p < 0.05) with a moderate agreement when considering only those patients referred from primary care to a specific diagnosis was obtained. CONCLUSIONS: Headaches are a very common reason for consultation in primary care (15%). The diagnostic agreement is moderate in our health sector so it is necessary to design training programs to help outline the criteria for referral to specialists and improve care for our patients.


TITLE: Estudio de concordancia diagnostica en cefalea entre neurologia y atencion primaria.Introduccion. La cefalea como sintoma es una patologia frecuente y uno de los principales motivos de consulta por parte de atencion primaria. Objetivo. Analizar las caracteristicas de los pacientes derivados desde atencion primaria a la consulta de neurologia general con cefalea o neuralgia como motivo de consulta, y la concordancia diagnostica. Pacientes y metodos. Estudio descriptivo transversal de todos los pacientes remitidos desde atencion primaria; se recogieron variables demograficas/clinicas y se compararon las hipotesis diagnosticas de atencion primaria y neurologia, determinando su concordancia. Resultados. Se remitieron desde atencion primaria 2.514 pacientes (588 de ellos con caracter preferente); en 378 casos el motivo de la consulta fue cefalea o neuralgia (42,46 años de media; el 77,8%, mujeres). En 139 pacientes se establecio tan solo un diagnostico semiologico y en el resto predominaron la migraña episodica (49,79%), la cefalea tensional cronica (18,41%) y la neuralgia del trigemino (12,13%). Desde neurologia, los diagnosticos mas frecuentes fueron, respectivamente, 33,86%, 24,05% y 18,67%. Se obtuvo un coeficiente kappa de 0,543 (p < 0,05), compatible con una concordancia moderada al considerar solo los pacientes remitidos desde atencion primaria con un diagnostico concreto. Conclusiones. Las cefaleas constituyen un motivo de consulta desde atencion primaria muy frecuente (15%). La concordancia diagnostica es moderada en nuestro sector sanitario, por lo que es necesario diseñar programas de formacion que ayuden a perfilar los criterios de derivacion al especialista y mejorar la atencion a nuestros pacientes.


Subject(s)
Headache/diagnosis , Neuralgia/diagnosis , Referral and Consultation , Adult , Cross-Sectional Studies , Female , Humans , Male , Migraine Disorders , Neurology , Primary Health Care
9.
Vet Parasitol ; 219: 40-3, 2016 Mar 30.
Article in English | MEDLINE | ID: mdl-26921037

ABSTRACT

The aim of this study was to evaluate the frequencies of Neospora caninum horizontal and vertical transmissions in beef cow-calf operations under three different extensive management systems: group A: 0.75 head per hectare pasturing on natural grass; group B: 1.1 head per hectare on natural grass and improved cultured pastures; and group C: 2 head per hectare on natural grass, improved cultured pasture and whole corn silage. Serum samples from 72 multiparous cows assigned to each beef cow-calf operations were obtained every 3 months during 2 years. A group of 30 replacement heifers from each group were tested similarly since they were 10-21 months old. Twenty four, 20 and 34 calves from groups A, B and C respectively, were bled before colostrum intake and again 6 months later. The samples were analyzed by indirect fluorescence antibody test (IFAT) for detection of total IgG against N. caninum at a serological titre ≥ 200 for multiparous cows and replacement heifers, and a serological titre ≥ 25 for calves. Serum samples from seropositive cows were assessed by ELISA to evaluate the avidity of their specific antibodies. There were no differences in the proportion of seropositive cows from groups A, B and C at the beginning of the trial (p>0.05). Interestingly, the lowest serological titres in seropositive cows from all groups were observed during the first trimester (p<0.05). Although seropositive cows had medium to high avidity antibodies, suggesting chronic infection; seroconversion associated with low antibody avidity was found in 2, 3 and 3 seropositive cows from groups A, B and C. All replacement heifers remained seronegative. No abortions were recorded but 2, 1, and 2 calves from groups A, B and C were seropositive before colostrum intake, respectively. Seropositive calves born from cows having intermediate or high avidity remained with the same serostatus at 6 months of age. Even under varying extensive management conditions, both N. caninum horizontal and vertical transmission methods do occur in beef cow-calf operations.


Subject(s)
Animal Husbandry , Cattle Diseases/epidemiology , Cattle Diseases/transmission , Coccidiosis/veterinary , Animals , Antibodies, Protozoan/blood , Argentina , Cattle , Coccidiosis/epidemiology , Coccidiosis/transmission , Disease Transmission, Infectious/veterinary , Female , Immunoglobulin G/blood , Infectious Disease Transmission, Vertical/veterinary , Neospora , Pregnancy , Random Allocation , Seroepidemiologic Studies
10.
Rev Neurol ; 59(9): 385-91, 2014 Nov 01.
Article in Spanish | MEDLINE | ID: mdl-25342051

ABSTRACT

INTRODUCTION: Patients with chronic migraine (CM) and medication abuse are difficult to treat, and have a greater tendency towards chronification and a poorer quality of life than those with other types of headache. AIM: To evaluate whether the presence of medication abuse lowers the effectiveness of topiramate. PATIENTS AND METHODS: A series of patients with CM were grouped according to whether they met abuse criteria or not. They were advised to stop taking the drug that they were abusing. Treatment was adjusted to match their crises and preventive treatment with topiramate was established from the beginning. The number of days with headache and intense migraine in the previous month and at four months of treatment was evaluated. RESULTS: In all, 262 patients with CM criteria were selected and 167 (63.7%) of them fulfilled abuse criteria. In both groups there was a significant reduction in the number of days with headache/month and number of migraine attacks/month at the fourth month of treatment with topiramate. The percentage of reduction in the number of days with headache/month in CM without abuse was 59.3 ± 36.1%, and with abuse, 48.7 ± 41.7% (p = 0.0574). The percentage of reduction in the number of days with intense migraine/month in CM without abuse was 61.2%, and with abuse, 50% (p = 0.0224). Response rate according to the number of days with headache/month in CM without abuse was 69%, and with abuse, 57%. Response rate according to the number of intense migraines/month in CM without abuse was 76.8%, and in CM with abuse, 61% (p = 0.0097). CONCLUSIONS: Topiramate was effective in patients with CM with and without medication abuse, although effectiveness is lower in the latter case.


TITLE: El abuso de farmacos en pacientes con migraña cronica influye en la efectividad del tratamiento preventivo con topiramato?Introduccion. Los pacientes con migraña cronica (MC) y abuso de medicacion son dificiles de tratar y tienen peor calidad de vida que otros pacientes con migrañas. Objetivo. Valorar si la presencia de abuso de farmacos disminuye la efectividad del topiramato. Pacientes y metodos. Una serie de pacientes con MC fueron agrupados segun presentasen criterios de abuso o no abuso de farmacos. Se les aconsejo la supresion del farmaco del cual abusaban. Se ajusto el tratamiento de sus crisis y se inicio tratamiento preventivo desde el principio con topiramato. Se valoro el numero dias con cefalea y migrañas intensas en el mes previo y al cuarto mes de tratamiento. Resultados. Fueron seleccionados 262 pacientes con criterios de MC, y de ellos 167 (63,7%) cumplieron criterios de abuso. En ambos grupos hubo una reduccion significativa del numero de dias con cefalea/mes y numero de crisis de migraña/mes al cuarto mes de tratamiento con topiramato. Porcentaje de reduccion de dias con cefalea/mes en MC sin abuso, 59,3 ± 36,1%; y con abuso, 48,7 ± 41,7% (p = 0,0574). Porcentaje de reduccion de migrañas intensas/mes en MC sin abuso, 61,2%; y con abuso, 50% (p = 0,0224). Tasa de respondedores segun numero de dias con cefalea/mes en MC sin abuso, 69%; y con abuso, 57%. Tasa de respondedores segun numero de migrañas intensas/mes en MC sin abuso, 76,8%; y en MC con abuso, 61% (p = 0,0097). Conclusiones. El topiramato fue efectivo en pacientes con MC sin y con abuso de farmacos, aunque con menor efectividad en estos ultimos.


Subject(s)
Analgesics/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Drug Overdose/complications , Fructose/analogs & derivatives , Headache Disorders, Secondary/complications , Migraine Disorders/prevention & control , Substance-Related Disorders/complications , Tryptamines/adverse effects , Adult , Analgesics/pharmacokinetics , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Drug Interactions , Female , Fructose/pharmacokinetics , Fructose/therapeutic use , Headache Disorders/drug therapy , Headache Disorders/prevention & control , Humans , Male , Middle Aged , Migraine Disorders/complications , Migraine Disorders/drug therapy , Patient Satisfaction , Topiramate , Treatment Outcome , Tryptamines/pharmacokinetics , Young Adult
12.
Rev Neurol ; 54(5): 277-83, 2012 Mar 01.
Article in Spanish | MEDLINE | ID: mdl-22362476

ABSTRACT

INTRODUCTION. Flunarizine, with level of evidence A, and nadolol, with evidence level C, would be indicated as preventive treatment of migraine. Yet, no previous studies have been conducted to compare the effectiveness of the two drugs. AIM. To compare the effectiveness parameters in independent groups of patients treated preventively with one of the pharmaceuticals from the study, the same protocol being applied in both cases. PATIENTS AND METHODS. The subjects selected for the study were patients with episodic migraine (according to 2004 International Headache Society criteria) who had undergone preventive treatment for the first time, with flunarizine (5 mg/day) or nadolol (20-40 mg/day). The main effectiveness variables (reduction in the number of seizures at four months of treatment and responder rates) were analysed. RESULTS. The study included 227 patients who intended to receive treatment: 155 with flunarizine (80.5% females; mean age: 38.3 ± 12.1 years) and 72 with nadolol (63.8% females; mean age: 37.1 ± 12.0 years). The mean number of seizures prior to treatment was 6.09 ± 2.6 in the flunarizine group and 5.1 ± 1.7 in the nadolol group (p = 0.0079); at four months of treatment it was 2.61 ± 2.4 in the flunarizine group and 2.77 ± 2.4 in the nadolol group (p = NS). Percentage of reduction of migraines: 55.2% with flunarizine and 50.4% with nadolol (p = NS). The responder rate was 69% with flunarizine and 67% with nadolol (p = NS). The excellent response rate (reduction in the number of seizures by 75% or more) was 52.2% with flunarizine and 36.1% with nadolol (p = 0.0077). Percentage of adverse side effects: 48.3% with flunarizine and 25% with nadolol (p = 0.0009). The satisfaction rate was similar in both groups, 68%. CONCLUSIONS. Both flunarizine and nadolol proved to be effective in the preventive treatment of episodic migraine. Flunarizine is used more often in our milieu and was less well tolerated.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Calcium Channel Blockers/therapeutic use , Flunarizine/therapeutic use , Migraine Disorders/prevention & control , Nadolol/therapeutic use , Adult , Female , Humans , Male
14.
Rev. neurol. (Ed. impr.) ; 49(5): 225-230, 1 sept., 2009. tab, graf
Article in Spanish | IBECS | ID: ibc-94820

ABSTRACT

Introducción. Los pacientes con cefalea y abuso de medicación (CAM) son difíciles de tratar, presentan mayor tendenciaa la cronificación y peor calidad de vida que los que cursan con otras cefaleas. Objetivo. Valorar los indicadores de respuesta de estos pacientes al tratamiento ambulatorio. Pacientes y métodos. De una serie de pacientes con migraña, seleccionamos aquéllos con criterios de CAM según el apéndice de la International Classification of the Headache Disease (ICHD-2) de 2006 y que nunca habían llevado previamente tratamiento. Ambulatoriamente, se les aconsejó la supresión del fármaco del que abusaban. Se ajustó el tratamiento de sus crisis con los fármacos más eficaces y se inició tratamiento preventivo desde el principio, con topiramato o flunaricina. Se agrupó a los pacientes según persistieran con CAM o no. Se valoró el número días con cefalea en el mes previo y al cuarto mes de tratamiento y la persistencia de abuso. Resultados. Cumplieron criterios de CAM 178 pacientes (edad media: 40,9 años; 88,7% mujeres). El 68,5% (122 pacientes) respondió y dejó de cumplir criterios de CAM tras el tratamiento. En ambos grupos, los tratamientos de sus crisis (triptanes, antiinflamatorios no esteroideos, analgésicos) y preventivos utilizados (topiramato o flunaricina) fueron similares. La media de días con cefalea previa al tratamiento fue de 18,52 en el grupo que respondió y de 20,87 (p = 0,0263) en el grupo que no respondió al tratamiento. Un 7,3% abandonó el tratamiento preventivo en el grupo de respondedores frente al 35% (p = 0,0001) en los no respondedores. Conclusiones. El mayor número de días con cefalea en el mes previo al tratamiento y el abandono del tratamiento preventivo fueron indicadores de mala evolución (AU)


Introduction. Patients with headache and medication abuse (HMA) are difficult to treat, have a greater tendency owards chronification and a poorer quality of life than those with other types of headache. Aim. To evaluate the indicators showing that these patients are responding to ambulatory treatment. Patients and methods. From a series of patients with migraine, we selected those who satisfied HMA criteria according to the appendix of the 2006 International Classification of the Headache Disease (ICHD-2) and who had never previously undergone treatment. As outpatients, they were advised to stop taking the drug that they were abusing. The treatment of their seizures was adjusted with the most efficient drugs and preventive treatment was started from the outset with topiramate or flunarizine. Patients were grouped according to whether they continued with HMA or not. Comparisons were made between the number of days with headache during the previous month and after four months of treatment and the persistence of abuse. Results. HMA criteria were met by 178 patients (mean age 40.9; 88.7% females). Results showed that 68.5% (122 patients) responded and no longer met HMA criteria after treatment. The treatment used for their seizures (triptans, nonsteroidal antiinflammatory drugs, analgesics) and preventive treatment (topiramate or flunarizine) were similar in both groups. The average number of days with headache prior to treatment was 18.52 in the group that responded and 20.87 (p = 0.0263) in the group that did not respond to treatment. In the group of responders 7.3% dropped out of preventive treatment compared with 35% (p = 0.0001) in the group of non-responders. Conclusions. A higher number of days with headache during the previous month and withdrawing from preventive treatment were indicators of a bad progression (AU)


Subject(s)
Humans , Headache Disorders, Secondary/drug therapy , Migraine Disorders/classification , Quality of Life , Flunarizine/therapeutic use , Chronic Disease/drug therapy , /statistics & numerical data , Risk Factors
15.
Rev Neurol ; 49(5): 225-30, 2009.
Article in Spanish | MEDLINE | ID: mdl-19714551

ABSTRACT

INTRODUCTION: Patients with headache and medication abuse (HMA) are difficult to treat, have a greater tendency towards chronification and a poorer quality of life than those with other types of headache. AIM. To evaluate the indicators showing that these patients are responding to ambulatory treatment. PATIENTS AND METHODS: From a series of patients with migraine, we selected those who satisfied HMA criteria according to the appendix of the 2006 International Classification of the Headache Disease (ICHD-2) and who had never previously undergone treatment. As outpatients, they were advised to stop taking the drug that they were abusing. The treatment of their seizures was adjusted with the most efficient drugs and preventive treatment was started from the outset with topiramate or flunarizine. Patients were grouped according to whether they continued with HMA or not. Comparisons were made between the number of days with headache during the previous month and after four months of treatment and the persistence of abuse. RESULTS: HMA criteria were met by 178 patients (mean age 40.9; 88.7% females). Results showed that 68.5% (122 patients) responded and no longer met HMA criteria after treatment. The treatment used for their seizures (triptans, nonsteroidal antiinflammatory drugs, analgesics) and preventive treatment (topiramate or flunarizine) were similar in both groups. The average number of days with headache prior to treatment was 18.52 in the group that responded and 20.87 (p = 0.0263) in the group that did not respond to treatment. In the group of responders 7.3% dropped out of preventive treatment compared with 35% (p = 0.0001) in the group of non-responders. CONCLUSIONS: A higher number of days with headache during the previous month and withdrawing from preventive treatment were indicators of a bad progression.


Subject(s)
Headache/chemically induced , Headache/drug therapy , Migraine Disorders/chemically induced , Migraine Disorders/drug therapy , Self Medication/adverse effects , Adult , Ambulatory Care , Female , Humans , Male , Treatment Outcome
16.
Rev Neurol ; 45(8): 456-9, 2007.
Article in Spanish | MEDLINE | ID: mdl-17948210

ABSTRACT

INTRODUCTION: Chronic daily headache (CDH) includes primary headaches that last more than four hours with a frequency equal or superior to 15 days a month over the last three months. It has a prevalence of 4-5% in the general population and is a frequent reason for visiting the physician in headache units. AIM: To evaluate the effectiveness of topiramate, as the primary drug, in CDH due to probable chronic migraine with or without medication abuse. PATIENTS AND METHODS: From the 447 patients with migraine in our database, we selected those: a) satisfying Silberstein criteria for CDH; b) that had not followed prior prophylactic treatment; and c) who were treated with topiramate as the primary drug. The mean number of days with headache and bouts of severe migraine in the fourth month of treatment using topiramate as compared to the month preceding treatment, as well as the percentage of responses and the rate of respondents in the fourth month were all analysed. RESULTS: Eighty-three patients (88% females) with a mean age of 38.0 +/- 14.13 years were selected. Medication abuse was reported in 44% of cases. At the fourth month of treatment, the mean number of days with headache dropped significantly from 20.8 to 7.9 (p < 0.0001) and the mean number of bouts of severe migraine diminished from 4.4 to 1.7 (p < 0.0001). The rate of respondents was 72%. Medication abuse continued in 14% of cases. Side effects were produced in 58% of patients and the dropout rate was 24%. CONCLUSIONS: Topiramate proved to be effective in the treatment of CDH due to probable chronic migraine and with probable medication abuse in de novo migraine patients.


Subject(s)
Anticonvulsants/therapeutic use , Fructose/analogs & derivatives , Headache/drug therapy , Migraine Disorders/drug therapy , Adult , Chronic Disease , Female , Fructose/therapeutic use , Humans , Male , Middle Aged , Topiramate
17.
Rev. neurol. (Ed. impr.) ; 45(8): 456-459, 16 oct., 2007. tab
Article in Es | IBECS | ID: ibc-65933

ABSTRACT

La cefalea crónica diaria (CCD) incluye aquellas cefaleas primarias de más de cuatro horas de duracióny frecuencia igual o superior a 15 días al mes en los últimos tres meses. Presenta una prevalencia del 4-5% entre la población general y es un motivo frecuente de consulta en las unidades de cefaleas. Objetivo. Valorar la efectividad de topiramato, como primer fármaco, en la CCD por probable migraña crónica con o sin abuso de fármacos. Pacientes y métodos. De nuestra base de datos de 447 pacientes con migraña se seleccionaron aquellos: a) con criterios de Silberstein de CCD, b) queno habían llevado un tratamiento profiláctico previo, y c) tratados con topiramato como primer fármaco. Se analizaron la media de días con cefalea y crisis de migraña intensa en el cuarto mes de tratamiento con topiramato en relación con el mes previoal tratamiento, los porcentajes de respuesta y la tasa de respondedores en el cuarto mes. Resultados. Se seleccionaron 83 pacientes (88% de mujeres) con una edad media de 38,0 ± 14,13 años. El 44% abusaba de fármacos. Al cuarto mes de tratamiento, la media de días con cefalea disminuyó significativamente de 20,8 a 7,9 (p < 0,0001) y la medía de crisis de migrañaintensa, de 4,4 a 1,7 (p < 0,0001). La tasa de respondedores fue del 72%. Un 14% continuó abusando de los fármacos. Se produjeron efectos adversos en el 58% de pacientes y hubo un 24% de abandonos. Conclusión. El topiramato se mostró efectivo en el tratamiento de la CCD por probable migraña crónica y con probable abuso de fármacos en pacientes migrañosos de novo


Chronic daily headache (CDH) includes primary headaches that last more than four hours with afrequency equal or superior to 15 days a month over the last three months. It has a prevalence of 4-5% in the general population and is a frequent reason for visiting the physician in headache units. Aim. To evaluate the effectiveness of topiramate, as theprimary drug, in CDH due to probable chronic migraine with or without medication abuse. Patients and methods. From the 447 patients with migraine in our database, we selected those: a) satisfying Silberstein criteria for CDH; b) that had not followed prior prophylactic treatment; and c) who were treated with topiramate as the primary drug. The mean number of days with headache and bouts of severe migraine in the fourth month of treatment using topiramate as compared to the monthpreceding treatment, as well as the percentage of responses and the rate of respondents in the fourth month were all analysed.Results. Eighty-three patients (88% females) with a mean age of 38.0 ± 14.13 years were selected. Medication abuse was reported in 44% of cases. At the fourth month of treatment, the mean number of days with headache dropped significantly from20.8 to 7.9 (p < 0.0001) and the mean number of bouts of severe migraine diminished from 4.4 to 1.7 (p < 0.0001). The rate of respondents was 72%. Medication abuse continued in 14% of cases. Side effects were produced in 58% of patients and thedropout rate was 24%. Conclusions. Topiramate proved to be effective in the treatment of CDH due to probable chronic migraine and with probable medication abuse in de novo migraine patients


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Migraine Disorders/drug therapy , Anticonvulsants/pharmacology , Headache/drug therapy , Migraine Disorders/epidemiology , Headache/epidemiology , Cross-Sectional Studies , Anticonvulsants/administration & dosage , Anticonvulsants/adverse effects
18.
Rev Neurol ; 26(152): 618-20, 1998 Apr.
Article in Spanish | MEDLINE | ID: mdl-9796018

ABSTRACT

INTRODUCTION: The antiepileptic drug gabapentin has begun to be used successfully in some cases of neuropathic pain. Its mechanism of action is still unknown, but seems to be related to a positive effect on the synthesis and liberation of the neurotransmitter GABA. CLINICAL CASES: Based on the observations of other authors, we used this drug in dosage varying between 900 and 1,200 mg/day, in three patients with neuropathic pain, of both central and peripheral origin, and in whom the usual treatments had been unsatisfactory or could not be tolerated because of side-effects. The patients had been diagnosed as having trigeminal neuralgia, post-herpetic neuralgia in the area of the first branch of the trigeminal nerve and a thalamic infarct which gave rise to a contralateral Déjerine-Roussy syndrome, respectively. In all three cases, administration of gabapentin was followed by such a striking improvement of the pain that co-adjuvant treatment could be reduced or stopped, with excellent tolerance and a minimal incidence of side-effects. CONCLUSIONS: Gabapentin should be borne in mind in the treatment of this type of pain, particularly when the usual treatment cannot be given or is insufficient to control pain, especially in elderly patients in whom there is often reduced tolerance of drugs.


Subject(s)
Acetates/therapeutic use , Amines , Analgesics/therapeutic use , Cyclohexanecarboxylic Acids , Neuralgia/drug therapy , gamma-Aminobutyric Acid , Aged , Aged, 80 and over , Gabapentin , Humans , Male , Middle Aged
19.
Rev Neurol ; 23(124): 1226-7, 1995.
Article in Spanish | MEDLINE | ID: mdl-8556623

ABSTRACT

Some non-steroid anti-inflammatory drugs, and especially diclofenac, may, in some susceptible patients bring about the appearance of segmentary myoclonic symptoms, which in some cases where there is kidney failure may cause real myoclonic encephalopathy. We present the case of a patient admitted into the nephrology service suffering from prerenal kidney failure as a result of dehydration. Once her kidney problems had been overcome and analytical parameters normalized, during treatment with diclofenac for inflammation of the lower left extremity arthritic in origin, she showed generalized myoclonic symptoms of action and attitude especially in the upper extremities. Neurologic examination showed no abnormalities other than certain drowsiness. General analysis and kidney function were normal, as was brain CT scan, EEG showed only a general tendency towards slowing down. Myoclonic symptoms completely disappeared in the next 24 hours after giving diclofenac up, the patient remaining neurologically asymptomatic and not showing a similar clinical picture in any subsequent check-up.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Diclofenac/adverse effects , Epilepsies, Myoclonic/chemically induced , Aged , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Arthritis/drug therapy , Arthritis/physiopathology , Brain/physiopathology , Diclofenac/therapeutic use , Epilepsies, Myoclonic/physiopathology , Female , Humans , Knee/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...